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Abstract
It is important for patients that treatments for diabetes not increase cardiovascular (CV) risk. The objective of this
analysis was to examine retrospectively the CV safety of exenatide BID, a GLP-1 receptor agonist approved for
treating hyperglycemia in patients with type 2 diabetes not adequately controlled with diet and exercise. Individual
participant data was pooled to assess the relative risk (RR) of CV events with exenatide BID versus a pooled
comparator (PC) group treated with either placebo or insulin from 12 controlled, randomized, clinical trials ranging
from 12-52 weeks. Mean baseline values for HbA1c (8.33-8.38%), BMI (31.3-31.5 kg/m
2), and duration of diabetes
(8 y) were similar between groups. Trials included patients with histories of microvascular and/or macrovascular
disease. Customized primary major adverse CV events (MACE) included stroke, myocardial infarction, cardiac
mortality, acute coronary syndrome, and revascularization procedures. The Primary MACE RR (0.7; 95% CI 0.38, 1.31),
calculated by the Mantel-Haenszel method (stratified by study), suggested that exenatide use (vs. PC) did not
increase CV risk; this result was consistent across multiple analytic methods. Because the trials were not designed
to assess CV outcomes, events were identified retrospectively from a list of preferred terms by physicians blinded
to treatment. Other limitations included the low number of CV events, the short duration of trials (≤1 y), and a
single active comparator (insulin). The results of these analyses are consistent with those of a recent retrospective
analysis of a large insurance database that found that patients treated with exenatide twice daily were less likely to
have a CV event than were patients treated with other glucose-lowering therapies.
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Background
Despite the numerous advancements in glucose-lower-
ing medications in recent years, the incidence of cardio-
vascular (CV) morbidity and mortality in patients with
type 2 diabetes has not consistently decreased [1]. In
2007, a controversial, widely publicized meta-analysis of
42 trials suggested that rosiglitazone, a thiazolidinedione
(TZD), was associated with increased risk of myocardial
infarction (MI) and death due to CV events [2-6]. At
that time, a joint advisory committee meeting concluded
that rosiglitazone increased myocardial ischemia and the
FDA added a black box warning to the rosiglitazone
label [2,7]. Although a non-inferiority CV outcomes
trial, RECORD concluded that rosiglitazone did not
increase CV morbidity or mortality compared with
other glucose-lowering medications [8]; the open-label
and unblinded design of RECORD prompted some to
question the quality of the data [7]. Following updated
meta-analyses and recent congressional inquiry, con-
cerns arose again about the CV safety of rosiglitazone
[9-12]. Recently, an advisory committee meeting (July
2010) concluded that rosiglitazone significantly
increased CV risk [7].
The risk-to-benefit profile of medications may begin
to take on greater importance for future approvals of
new drugs [13,14]. Exenatide twice daily (exenatide BID)
was the first GLP-1 receptor agonist approved for treat-
ment of hyperglycemia in patients with type 2 diabetes
not adequately controlled with diet and exercise, sulfo-
nylurea (SFU), TZD, or metformin (MET; alone, or with
an SFU, or TZD). In addition to glycemic control and a
low risk of hypoglycemia, exenatide may favorably affect
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profiles, and body weight [15-17]. Because the incidence
of CV events was low in each of the clinical trials, we
undertook this pooled analysis to provide an integrated
assessment of the CV safety data from 12 studies with
exenatide BID.
Methods
Study Selection
For each clinical trial, a protocol was approved by an
institutional review board, in accordance with the prin-
ciples described in the Declaration of Helsinki (World
Medical Association 1997). Each of the trials included in
this analysis was conducted by Amylin Pharmaceuticals,
Inc. and Eli Lilly and Company. Complete efficacy and
safety data for these trials have been reported previously
[18-29]. Randomized, controlled trials (8 blinded, 4
open-label) that were completed by September 30, 2008
and of at least 12 weeks in duration, that were included
in this analysis were designed to compare the efficacy
and tolerability of exenatide BID to placebo or insulin
(Table 1). They were either placebo-controlled or active-
controlled studies where insulin served as the compara-
tor. The studies included in this analysis were not
designed to assess CV events and events were not pro-
spectively adjudicated.
Analysis population
The current analyses included patients from the intent-
to-treat populations (i.e., patients who received at least 1
dose of randomized study medication) of each study
(Table 1). Patients in all studies had type 2 diabetes and
were treated continuously with exenatide and MET,
SFU, or TZD alone or in combination. All patients were
18 to 75 years-of-age, had a HbA1c ≤11.0%, a body mass
index (BMI) of 25 to 45 kg/m
2, and a history of stable
body weight (≤10% change) for at least 3 months.
Patients were excluded if they had used weight loss
drugs or had evidence of a significant medical condition.
Investigators were asked to exclude patients with evi-
dence of active cardiac disease within 1 year prior to the
study, i.e., MI, clinically significant arrhythmia, unstable
angina, moderate to severe congestive heart failure, cor-
onary artery bypass surgery, or angioplasty. Patients
with a >1 year history of MI, transient ischemic attack
or large vessel disease or with a history of microvascular
disease were eligible for enrollment. All patients pro-
vided written informed consent before participation.
Outcomes
Events were identified by preferred terms according to
the Medical Dictionary for Regulatory Activities (Med-
DRA 11.0). A team of physicians, blinded to treatment,
independently reviewed the list of preferred terms
prior to the analyses to focus on the terms most likely
to represent true events of interest, regardless of
occurrence. Blinded adjudication of the CV events was
not pre-specified in the study protocols; therefore,
events were identified retrospectively using the pre-
specified list of preferred terms independent of
whether or not the events had occurred. At the time
of the occurrence during the original trial, the events
Table 1 Summary of controlled studies included in CV analysis
Exenatide† Placebo or Comparator
Study/Registry Number Diabetes Management Duration* (Weeks) ITT (N) Exposure (SY) ITT (N) Exposure (SY)
DeFronzo et al, 2005
18 NCT00039013 Met 30 223 113.8 113 57.8
Buse et al, 2004
20 NCT00039026 SFU 30 254 123.2 123 55.1
Kendall et al, 2005
19 NCT00035984 Met + SFU 30 486 254.9 247 122.2
Zinman et al, 2007
24 NCT00099320 TZD ± Met 16 121 31.7 112 32.3
Kadowaki et al, 2008
27 NCT00382239 SFU ± Met 12 111 23.9 40 9.2
Gao, et al, 2009
26 NCT00324363 Met ± SFU 16 234 65.5 233 67.3
Moretto et al, 2008
28 NCT00381342 D + E 24 155 65.2 77 33.1
Gill et al, 2010
29 NCT00516074 Met and/or TZD 12 28 5.8 26 5.7
Heine et al, 2005
22 NCT00082381 Met + SFU 26 282 122.5 267 124.6
Nauck et al, 2007
23 NCT00082407 Met + SFU 52 253 220.1 248 228.6
Davis et al, 2007
25 NCT00099333 SFU or Meg and/or Met 16 33 7.7 16 5.2
Barnett et al, 2007
21 NCT00099619 Met or SFU 16‡ 136 37.3 127 38.9
Totals –– 2,316 1,071.6 1,629 779.9
D + E = diet and exercise therapy; ITT = Intent-to-Treat Population; Meg = meglitinide; Met = metformin; OAD = oral antidiabetic medications; SFU =
sulfonylurea; TZD = thiazolidinedione.
*Duration of treatment with randomized study medication.
†Includes treatment with exenatide 2.5 mcg or 5 mcg BID for duration of study, or 4 weeks of exenatide 5 mcg BID followed by exenatide 10 mcg BID for
remainder of study.
‡NCT00099619 had a crossover design, with 16 weeks per period (exenatide or insulin glargine).
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cal trial monitoring and follow-up of adverse events,
laboratory evaluations, physical examinations, vital
signs measurements, with particular attention to ser-
ious adverse events.
All data for patients who died were examined to
ascertain if the underlying cause was CV in nature
b a s e do nt h ep r e f e r r e dt e r mp r o v i d e da n dt h ec a s e s
were reviewed in detail. “Sudden deaths” were adjudi-
cated as CV events, in conformance with most large CV
outcomes trials [30-35]. The final list of terms was con-
cordant with the FDA list presented at the advisory
committee meeting in April 2009 for other antidiabetic
agents [36].
Primary Outcome
T h ep r i m a r yo u t c o m ew a sP r i m a r yM a j o rA d v e r s eC V
Events (MACE); per FDA guidance, it included terms
reflective of CV mortality, stroke, myocardial infarction,
acute coronary syndrome, and revascularization
procedures.
Secondary Outcome
The secondary CV endpoint included all relevant CV
adverse events. This expanded endpoint comprised all
terms of the Primary MACE endpoint plus terms for
arrhythmia, heart failure (with or without hospitaliza-
tion), and mechanical-related events. Mechanical-related
events were aortic valve disease, aortic valve stenosis,
cardiac failure congestive, cardiomegaly, CV disorder,
heart valve incompetence, left atrial dilatation, mitral
valve incompetence, and tricuspid valve incompetence.
Heart failure and mechanical-related adverse events
were included in an effort to encompass as many poten-
tially important CV-related events as possible.
Analysis
A meta-analysis was performed on 12 completed longer-
term (3- to 12-month), randomized, placebo- or insulin
comparator-controlled trials of exenatide BID, in accor-
dance with the FDA guidelines [37]. Data from approxi-
mately 4,000 patients with type 2 diabetes and an
average exposure of 24 weeks were included [18-29].
Pooled data from placebo- and insulin-treated patients
were compared with pooled data from exenatide-treated
patients. The exenatide cohort included participants
randomized to receive exenatide BID 2.5 mcg (n = 37),
5 mcg (n = 594), or 10 mcg (n = 1,685). Because of the
low number of CV events, the 3 exenatide dose groups
were combined.
For the primary analysis, the Relative Risk (RR) of an
incident CV event and the corresponding 95% confidence
interval (CI) were calculated using Mantel-Haenszel
method stratified by study. In order to demonstrate
robustness, the RR and its 95% CI were calculated using
the following additional methods: pooled RR (without
stratification by study and with common continuity cor-
rection [i.e., adding 0.5 to all cells if one of the treatment
groups had no events]) and Shuster’s RR [38] (weights all
trials equally and included studies with no events). The
Hazard Ratio (HR) was calculated using 2 methods: 1)
the Cox proportional hazard model (time to first event)
with adjustment for study, and 2) the Andersen-Gill
model (recurrent events) with adjustment for study.
Ninety-five percent CIs for the RR and HR were provided
at a 2-sided significance level of 0.05. Weighted Kaplan-
Meier survival curves were generated to show the time to
first event and the proportion of patients who were risk-
free over time [39]. The time to event was calculated
from the first randomized dose to the time of the first
cardiac event. Exposure Adjusted Incidence Rate (EAIR)
and its 95% CI were calculated using the Exact method
[40]. The RR and its 95% CI based on EAIR and event
rate were provided [41].
Additional subgroup analyses by age (<65 vs. ≥65),
BMI (<30 vs. ≥30), and renal function (normal, mild
impairment, and moderate impairment) were provided
to assess the effects of these baseline characteristics.
SAS 9.2
® (Statistical Analysis Software, Cary, NC, USA)
was used for all analyses.
Results
The data included in these analyses represented 1,072
patient-years (PY) exposure with exenatide BID (N =
2,316) and 780 PY exposure with comparators (placebo,
n = 971; insulin, n = 658). Demographic and baseline
characteristics were similar between treatment groups
(Table 2). Participants had similar mean baseline values
for HbA1c (8.33%-8.38%), BMI (31.3-31.5 kg/m
2), and
duration of diabetes (8 years). Of note, the mean systolic
blood pressures at baseline for both cohorts were 131 ±
4m mH ga n d1 3 2±5m mH gf o rt h ee x e n a t i d ea n d
the pooled comparator cohorts, respectively. Some
patients had a past history of CV disease (including
multiple events) and/or microvascular disease (including
multiple conditions). From baseline to endpoint, heart
rate changes were +0.5 ± 9.8 beats per minute (bpm)
for exenatide and +0.1 ± 9.2 bpm for the pooled com-
parators (mean ± SD).
Incidence rates of Primary MACE were similar for
5 mcg (0.9%) and 10 mcg (1.1%) exenatide dose groups,
and no events were observed in the 2.5 mcg group.
Therefore, data from all exenatide doses (2.5 mcg,
5 mcg, 10 mcg) were pooled in the analyses. The EAIR
for exenatide treatment group was 18.73 per 1,000
patient-years versus 23.17 per 1,000 patient-years for the
pooled comparator group (Table 3). Overall, 26 partici-
pants experienced serious adverse CV events: 15 (0.6%)
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parator group (data not shown). Four fatal CV events
occurred: 2 in the exenatide group (MI, atrial fibrilla-
tion) and 2 in the comparator group (MI, cerebrovascu-
lar accident).
The point estimates for Primary MACE and Secondary
CV endpoints between exenatide BID and the pooled
comparator were both 0.7 (the upper limits of the 95%
CIs were 1.3 and 1.0, respectively), in favor of exenatide
(Figure 1). These results suggest that exenatide did not
increase the CV risk. For the individual studies, the
point estimates for RR were <1.0 (favoring exenatide)
for 10 of 12 long-term controlled studies (Figure 2). In
addition, the RRs and 95% CIs for the Primary MACE
were consistent across multiple methods of analysis
(including sensitivity analyses of RR based on incidence
and RR based on EAIR event rate), with point estimates
ranging from 0.5 to 0.8, and the upper limit of the 95%
CIs ranging from 1.3 to 1.5 (Figure 3). Similar point
estimates were observed for the broader secondary CV
endpoint; however, the upper limit of the 95% CI was
<1.3 for all methods (Figure 3). A weighted Kaplan-
Meier plot shows that a significantly higher percentage
of exenatide-treated patients than pooled comparator-
treated patients were free of a primary MACE event
over 1 year (P < 0.0001; Figure 4).
Discussion
Assessing the CV Risk of Glucose-Lowering Therapies
One of the strengths of this meta-analysis is the use of
individual participant data from each of the trials, in
contrast with a typical meta-analysis in which summary
statistics for individual studies are used. Another
strength was the use multiple methods of analysis, some
of which allowed for the inclusion of studies with zero
Table 2 Baseline characteristics and demographics
Baseline Characteristics Exenatide (N =
2,316)
Pooled Comparator
(N = 1,629)
Gender, M/F (%) 56/44 53/47
Race (%)
Caucasian 64 65
Black 6 4
Hispanic 11 10
Asian 19 20
Other 1 1
Age (years) 56 ± 10 56 ± 10
≥65 years (%) 21 20
Duration of Diabetes
(years)
8±6 8±6
≥10 years (%) 32 35
Weight (kg) 89.1 ± 20.3 87.8 ± 19.8
Body Mass Index (BMI [kg/
m
2])
31.5 ± 5.6 31.3 ± 5.4
BMI <30 kg/m
2 (%) 44 45
BMI ≥30 kg/m
2 (%) 56 55
HbA1c (%) 8.33 ± 1.06 8.38 ± 1.07
Systolic Blood Pressure
(SBP [mm Hg])
131 ± 4 132 ± 5
Diastolic Blood Pressure
(DBP [mm Hg])
79 ± 2 79 ± 1
Heart Rate (beats per
minute)
75 ± 9 75 ± 9
Renal Function
Impairment* (%)
None 86 86
Mild 13 14
Moderate 1 1
Data are mean ± SD unless otherwise noted. Percentages may not add to 100
due to rounding.
*Renal function is defined based on creatinine clearance (CrCl) as calculated
by the Cockcroft-Gault equation: normal, CrCl >80 mL/min; mild impairment,
CrCl >50-80 mL/min; moderate impairment, CrCl >30-50 mL/min.
Table 3 Incidence rates and exposure-adjusted incidence rates for primary MACE and secondary CV endpoints
Primary MACE Endpoint Secondary MACE Endpoint
Exenatide
(N = 2,316)
Pooled Comparator
(N = 1,629)
Exenatide
(N = 2,316)
Pooled Comparator
(N = 1,629)
Primary Analyses
Incidence (n) 20 18 46 42
Incidence (n/N) 0.009 0.011 0.020 0.026
RR (95% CI) 0.70 (0.38, 1.31) 0.69 (0.46, 1.03)
Secondary Analysis
EAIR (per 1,000 years) 18.73 23.17 43.37 54.37
RR (95% CI) 0.81 (0.43, 1.53) 0.80 (0.53, 1.21)
Event Rate (per 1,000 years) 22.40 28.21 54.13 66.67
RR (95% CI) 0.79 (0.45, 1.42) 0.81 (0.56, 1.18)
CI = confidence interval; CV = cardiovascular; EAIR = exposure-adjusted incidence rate; MACE = major adverse cardiovascular events; RR = risk ratio.
RR for the incidence was calculated using the Mantel-Haenszel estimate with study as a stratification factor.
EAIR and event rate were calculated based on the Exact method, with corresponding RR calculated using the log-normal approximation.
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a preliminary assessment of the CV risk associated with
exenatide treatment across trials used for registration.
Because these findings are not conclusive, a prospective,
adequately-powered, adjudicated, CV outcome study
(NCT01144338) of the investigational once-weekly for-
mulation of exenatide was initiated.
Applying the FDA guidance on how to assess CV
safety in the development of treatments for type 2 dia-
betes to this analysis, the HR point estimates were both
<1 for the Primary MACE and Secondary CV endpoints
resulting from the lower observed incidence of CV
events with exenatide BID compared to the control
group [37]. These results statistically excluded a 1.8-fold
increase of the CV risk by exenatide and were consistent
with the FDA guideline that state that the upper limit of
a 2-sided 95% CI for new diabetes therapies should be
<1.8. In fact, the results suggest that exenatide treatment
may improve CV outcomes, although this effect failed to
reach statistical significance. Our results are consistent
with those of a recent retrospective analysis of a large
insurance database in which the 39,275 patients treated
with exenatide twice daily were found to be significantly
l e s sl i k e l yt oh a v eaC Ve v e n tt h a nw e r et h e3 8 1 , 2 1 8
patients treated with other glucose-lowering therapies
(HR 0.81, 95% CI 0.68-0.91, P = 0.01) [42]. Although
the results of the current meta-analysis suggest that
there may be an association between exenatide and
improved CV outcomes, data from multi-year, rando-
mized, controlled, adequately-powered clinical trials
with prospective blinded adjudication of CV events are
• RR exenatide BID vs. all placebo or comparator studies
Per FDA guidance, if upper limit of 95% CI <1.3 a post-marketing safety study may not be required; 
WRDSRVW-marketing study may be required to demonstrate <1.3, ODUJHVDIHW\VWXG\
may be required prior to approval.
0.0 0.5 1.0 1.5 2.0 1.3 1.8
Primary MACE
Secondary CV
Exenatide Better Comparator Better
0.38 0.70 1.31
0.46 0.69 1.03
Risk Ratio
Figure 1 Risk of primary MACE and secondary CV endpoints
with exenatide BID relative to pooled comparators.
Study
Exenatide
n/N (%)
Placebo or 
Comparator
n/N (%) RR
Defronzo et al, 200518 1/223 (0.45) 5/113 (4.42) 0.10
Buse et al, 200420 4/254 (1.57) 1/123 (0.81) 1.94
Kendall et al, 200519 8/486 (1.65) 5/247 (2.02) 0.81
Kadawaki et al, 200927 0/111 (0.00) 1/40 (2.50) 0.12
Zinman et al, 200724 0/121 (0.00) 0/112 (0.00) 0.93
Gao, et al, 200926 1/234 (0.43) 2/233 (0.86) 0.50
Moretto et al, 200828 0/155 (0.00) 0/77 (0.00) 0.50
Gill et al, 2010 29 0/28 (0.00) 0/26 (0.00) 0.93
All Placebo controlled 14/1612 (0.01) 14/971 (0.01) 0.53
Heine et al, 200522 1/282 (0.35) 1/267 (0.37) 0.95
Nauck et al, 200723 5/253 (1.98) 3/248 (1.21) 1.63
Davis et al, 200725 0/33 (0.00) 0/16 (0.00) 0.50
Barnett et al, 200721 0/136 (0.00) 0/127 (0.00) 0.93
All Comparator controlled 6/704 (0.01) 4/658 (0.01) 1.46
Totals 20/2316 (0.86) 18/1629(1.10) 0.70
0.001 0.01 0.1 1 10 1.8
Exenatide Better Comparator Better
Risk Ratio
• RR exenatide BID vs placebo or comparator by individual study; Ƒ RR exenatide BID vs All placebo studies; 
¸ RR exenatide vs All comparator studies; Ŷ RR exenatide BID vs All placebo or comparator studies
Figure 2 Incidence and RR for primary MACE with exenatide use by individual study.
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tive effects.
Despite the increased relative risk of CV disease in
diabetes, the absolute risk m a yo n l yb er e d u c e dw h e n
multifactorial treatment strategies are used [43-45];
therefore, the CV risk associated with glucose-lowering
agents is not easily ascertained. Even in randomized,
controlled trials that included CV outcomes as part of
the endpoint, the outcomes may be difficult to interpret.
The University Group Diabetes Program (UGDP) sug-
gested treatment with tolbutamide, a first generation
SFU, was associated with increased risk of negative CV
outcomes [46]. Despite the limitations of UGDP, the
implication that SFUs were associated with some risk
remained until the results of the landmark UKPDS were
available [47]. From UKPDS, it was evident that SFU or
MET monotherapy was associated with reduced CV
risk; however, treatment with the combination of SFU
and MET was associated with increased CV risk [48].
Demonstration of the impact of glycemic control on the
risk of acute MI was limited by the relatively low abso-
lute MI event rate, but long-term follow-up studies of
UKPDS and DCCT found that intense glycemic control
reduced major CV events [31,49,50].
Four large trials have analyzed the effects of glucose
lowering on CV risk [30,31,35,47,49,51]. The UKPDS
studied patients early in the course of disease and
found that intensive therapy was associated with a
reduction in CV events, especially in the small cohort
of obese patients who were treated with metformin
[47,49]. The 3 large trials (ADVANCE, ACCORD, and
VADT) in patients with longer duration of disease gen-
erally had HRs less than 1.0 with intensive therapy, but
none achieved statistical significance [30,35,51]. The
systematic review of these 4 trials in a pooled analysis
did show a reduction in CV disease (RR 0.90, 95% CI
• RR exenatide BID vs. all placebo or comparator studies
Sensitivity analyses included the pooled RR without stratification by study, and Shuster’s method, which weights all trials equally.
Hazard ratios (HRs) and 95% CIs were obtained from the Cox proportional hazard regression model and the Andersen-Gill model, 
with adjustment for study.
Endpoint/ Method RR (95% CI)
Primary MACE
RR (Mantel-Haenszel) 0.70 (0.38, 1.31)
HR (Cox) 0.71 (0.36, 1.37)
HR (Andersen-Gill) 0.69 (0.39, 1.25)
RR (Pooled) 0.78 (0.42, 1.47)
RR (Shuster) 0.53 (0.21, 1.35)
Secondary CV endpoint
RR (Mantel-Haenszel) 0.69 (0.46, 1.03)
HR (Cox) 0.68 (0.44, 1.04)
HR (Andersen-Gill) 0.69 (0.47,1.01)
RR (Pooled) 0.77 (0.51, 1.17)
RR (Shuster) 0.44 (0.22, 0.86)
Risk Ratio
1.3 1.8 0.0 0.5 1.0 1.5 2.0 1.3 1.8
Figure 3 Forest plot of CV end points by statistical method.
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Figure 4 Weighted Kaplan Meier plot for subjects without a
primary MACE event by treatment in controlled studies of
exenatide BID.
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Page 6 of 100.83-0.98) and coronary heart disease (RR 0.89, 95% CI
0.81-0.96), but not in stroke, coronary heart failure,
CV disease mortality, or all-cause mortality [52].
A C C O R Da n dV A D Tr e p o r t e dt h a tm o r t a l i t yw a sa s s o -
ciated with hypoglycemia [35,51,53]. In fact, ACCORD
was discontinued because of this increased mortality.
Hypoglycemia in each of the arms of the ACCORD
trial was associated with increased mortality, though
hypoglycemia did not explain the increased mortality
risk in the intensive arm [53]. Recently, lower HbA1C
values in the intensive arm were reported to be asso-
ciated with reduced CV disease events [54] and diffi-
culty in lowering HbA1C b e l o w7 %i nt h ei n t e n s i v e
group may actually have been the best predictor of CV
events [54]. None of the trials in patients with longer
duration of disease demonstrated a clear adverse (or
beneficial) effect of any particular glucose-lowering
medication, although the trials were not designed to
answer this question. However, a reasonable interpre-
tation is that there may be small to modest benefits on
CV disease events with glucose lowering as long as
such glucose lowering can be achieved without
increased risk for hypoglycemia. In addition, the diffi-
culty in understanding the results of the recent CV
trials may be due, in part, to the declining incidence
rate of CV events in patients with diabetes. The declin-
ing event rates observed in the most recent CV studies
may suggest that improvements to CV risk may be due
to other temporal phenomena. Resolving the problem
of residual risk is increasingly difficult to prove experi-
mentally because the low absolute risk of an event
requires large numbers of subjects to be followed for a
long period of time with a disease that progresses and
requires evolving therapeutic intervention.
Potential CV Effects of GLP-1 Receptor Agonists
Potential mechanisms of CV disease protection by GLP-
1 in humans have been proposed but not established.
One possibility is glycemic control, given the positive
correlation between HbA1C and CV events [55,56].
Another possibility is the association of GLP-1 receptor
agonist treatment with weight stability or reduction.
Although the effects of weight gain in treated patients
with type 2 diabetes have not been thoroughly investi-
gated, an observational study showed that CV disease
risk in patients with type 2 diabetes increased with
increasing BMI [57]. Although the majority of patients
with type 2 diabetes are overweight and at greater risk
of CV disease than are patients without type 2 diabetes
[58], most conventional diabetes medications are weight
neutral or induce weight gain [59,60].
Improving glycemic control, supporting weight loss,
and minimizing hypoglycemia are the clinical priorities
in the management of most patients with type 2
diabetes [61]. During the last decade, exenatide BID
therapy has been consistently associated with improve-
ments in glycemic control coupled with weight loss in
clinical and observational studies of patients with type 2
diabetes [62,63]. Importantly, exenatide therapy does
not increase the risk of severe hypoglycemia when used
in the absence of agents commonly associated with
hypoglycemia, primarily SFU and insulin. In several
small studies, insulin-induced hypoglycemia was asso-
ciated with lengthened QT intervals, which may increase
the risk of arrhythmia [64,65]. It is possible that the low
risk of hypoglycemia with GLP-1 receptor agonist treat-
ments may contribute to a lower risk of CV events.
Exenatide therapy has been associated with reductions
in multiple cardiovascular risk factors. A pooled analysis
of randomized controlled clinical trials of exenatide BID
demonstrated a significant reduction in systolic blood
pressure with exenatide therapy compared with placebo
or insulin therapy [66]; a similar result was obtained in
a recent randomized controlled clinical trial [67]. In
open-label extension studies lasting up to 3 years, exe-
natide BID treatment resulted in improved glycemic
control accompanied by moderate weight loss and
improvements in BP, cholesterol levels, inflammatory
markers, and insulin resistance for some patients
[15-17]. Improvements in postprandial lipidemia asso-
ciated with exenatide treatment were identified in a
1-year open-label study that compared the efficacies of
exenatide and insulin glargine [68,69]. Compared with
insulin-treatment, significant decreases in post-prandial
triglycerides, free fatty acids, HDL-C, VLDL-C, and Apo
B48 were observed with exenatide treatment. No
between-group differences were found in postprandial
total cholesterol, LDL-C, ApoA1, ApoA2, Apo B100, or
ApoC3, although exenatide reduced the post-prandial
oxidative stress markers P-malondialdehyde and oxi-
dized LDL [68]. Reductions in high-sensitivity C-reactive
protein and increases in total adiponectin were also
observed [69]. The latter changes were not statistically
dependent on changes in fat mass or body weight [69].
Exenatide therapy has been associated with 1 or
2 bpm increases in heart rate in individual clinical trials
[29,67]. In this analysis, mean heart rate changes were
+0.5 bpm for exenatide and +0.1 bpm for the pooled
comparators. The clinical importance of small increases
in heart rate is unclear. The majority of epidemiological
studies in patients with diabetes have studied the effects
of 10 bpm increases in heart rate from any cause, which
are associated with increased CV risk [70,71].
No effects of exenatide BID on cardiac repolarization
(QT/QTc interval) have been observed in preclinical
toxicology studies or during clinical studies of exenatide
BID in patients with type 2 diabetes. A thorough QT
study in healthy volunteers demonstrated that,
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ment was not associated with clinically significant QTc
prolongation [72]. A thorough QT study for an investi-
gational, long-acting formulation of exenatide is
ongoing.
Extrapolating from pre-clinical studies, it is possible
that GLP-1 receptors located in the heart and vascula-
ture may play a protective role with respect to CV dis-
ease [73,74]. In animal models, GLP-1 reduced infarct
size after coronary artery ischemia [75], improved left
ventricular ejection volume in heart failure [73],
improved glucose uptake in the myocardium [74], and
induced nitric oxide-independent vasorelaxation in the
endothelium [74]. Recent studies evaluated treatment
with a GLP-1 receptor agonist in rodent models of
severe hypertension or congestive heart failure. Dahl
salt-sensitive rats fed a high-salt diet were found to have
less hypertension, renal dysfunction, and mortality after
4 weeks of continuous therapy with a GLP-1 analog
than were those without treatment [76]. Similarly, rats
with heart failure after coronary artery ligation that were
treated with a GLP-1 analog demonstrated improved
cardiac function, cardiac dimension, exercise capacity,
and survival compared to untreated rats [77]. In
humans, there is limited evidence that GLP-1 improves
left ventricular ejection fraction, reperfusion, or func-
tional status in patients with heart failure or MI [78,79].
Further studies are warranted in patients with specific
types of CV disease to understand if the latter effects
and those on the endothelium are seen in humans. Stu-
dies of the CV effects of different formulations of GLP-1
receptor agonists, including an oral formulation, are also
justified to determine whether similar results are seen in
all members of this drug class [80].
Limitations
Major limitations of this analysis were the inclusion of
studies of short duration, lack of complete data on CV
history, and the lack of pre-specified and blinded adjudi-
cation of the CV events. In addition, the incidence of
CV events was low in the individual trials. As with all
meta-analyses, the current meta-analysis was retrospec-
tive in nature. Pooling the placebo group with a single
active-comparator group is another potential limitation
of this analysis. The rationale for pooling the placebo-
and active-comparator patients was to provide greater
power for this analysis by increasing the sample size and
the number of observed outcomes.
Conclusions
On the basis of this integrated analysis of 3,945 partici-
pants representing 1,070 patient-years of exenatide
exposure and 780 patient-years of PC exposure, no
increase in CV risk was associated with use of exenatide
BID (vs. PC) in patients with type 2 diabetes participat-
ing in clinical trials. This analysis, conducted in compli-
ance with FDA guidance on the subject, provides insight
into the CV safety of exenatide treatment.
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